Forward Perspectives on Integrating QCS and TROP2 NMR Into Future Treatment Approaches

Implementing new targeted therapies based on advanced biomarker testing requires a strategic and prioritized approach to diagnostic workflows. Initially, pathologists must perform essential histologic stains to identify the cancer type and differentiate it from metastases or other malignancies. Following this, NGS is critical for gathering comprehensive molecular information to guide frontline treatment decisions, particularly regarding targeted therapies and immunotherapy eligibility. Because tissue samples are often limited, it’s important to carefully sequence testing, prioritizing NGS early on and reserving IHC panels such as HER2 or MET for subsequent lines of therapy if tissue availability is constrained.

Tissue scarcity is an ongoing challenge, requiring innovation in both testing protocols and collaboration between clinical teams. Liquid biopsies are increasingly used alongside tissue biopsies to obtain rapid molecular insights while conserving precious tissue for IHC and other tests that require physical slides. New technologies are emerging to optimize tissue triage by assessing tumor content on unstained slides, enabling quick decisions about whether there is enough material for comprehensive testing. Multiplex IHC methods are also being explored to test multiple markers simultaneously, maximizing the diagnostic yield from limited tissue samples. These advances aim to reduce repeat biopsies and improve turnaround times, ultimately enhancing patient care.

Effective communication and partnership between oncologists and pathologists are crucial to navigating the complexities of biomarker-driven care. As drug approvals rapidly evolve, often tied to specific biomarker results, streamlined workflows and clear reporting structures will help ensure timely, actionable results. Collaborative efforts can minimize redundant testing and tissue wastage, making the entire diagnostic and treatment process more efficient. This multidisciplinary coordination will be vital to integrating new biomarker tests into clinical practice and delivering personalized therapy to patients in a timely manner.